Evidence map›Paper›PMID 39863615›Full record

ArticleNature communications2025

Mechanisms of multidrug resistance caused by an Ipi1 mutation in the fungal pathogen Candida glabrata.

Taiga Miyazaki, Shintaro Shimamura, Yohsuke Nagayoshi, Hironobu Nakayama, Akihiro Morita, Yutaka Tanaka, Yasuhiko Matsumoto, Tatsuo Inamine, Hiroshi Nishikawa, Nana Nakada and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Mechanism of azole resistance inJournal of medical microbiology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Taiga Miyazaki *Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. taiga_miyazaki@med.miyazaki-u.ac.jp.ORCID http://orcid.org/0000-0002-0962-5758
Shintaro Shimamura *Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. sshimamu@marianna-u.ac.jp.
Yohsuke Nagayoshi *Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hironobu NakayamaFaculty of Pharmaceutical Sciences, Suzuka University of Medical Sciences, Mie, Japan.ORCID http://orcid.org/0000-0001-7444-1173
Akihiro MoritaFaculty of Pharmaceutical Sciences, Suzuka University of Medical Sciences, Mie, Japan.
Yutaka TanakaDepartment of Infection and Host Defense, Tohoku Medical and Pharmaceutical University, Miyagi, Japan.ORCID http://orcid.org/0000-0003-2944-8485
Yasuhiko MatsumotoDepartment of Microbiology, Meiji Pharmaceutical University, Tokyo, Japan.
Tatsuo InamineDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroshi NishikawaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nana NakadaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID http://orcid.org/0000-0002-2508-0882
Makoto SumiyoshiDivision of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Tatsuro HirayamaDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Shigeru KohnoDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Funding

Japan Agency for Medical Research and Development (AMED) JP21fk0108094Japan Agency for Medical Research and Development (AMED) JP24fk0108700Merck & Co., Inc. | MSD K.K. #57467MEXT | Japan Society for the Promotion of Science (JSPS) JP19K07540
6 · The paper itself

Abstract

Multidrug resistance in the pathogenic fungus Candida glabrata is a growing global threat. Here, we study mechanisms of multidrug resistance in this pathogen. Exposure of C. glabrata cells to micafungin (an echinocandin) leads to the isolation of a mutant exhibiting resistance to echinocandin and azole antifungals. The drug-resistant phenotype is due to a non-synonymous mutation (R70H) in gene IPI1, which is involved in pre-rRNA processing. Azole resistance in the ipi1

Indexed as

Antifungal AgentsCandida glabrataDrug Resistance, Multiple, FungalFungal ProteinsAzolesEchinocandinsGene Expression Regulation, FungalMicafunginMicrobial Sensitivity TestsMutationSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsAntifungal AgentsAzolesEchinocandinsFungal ProteinsMicafunginSaccharomyces cerevisiae Proteins

Identifiers

PMID39863615
PMCPMC11763052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.